Stroke Prevention and Treatment for Youth with Sickle Cell Anemia: Current Practice and Challenges and Promises for the Future

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2024 Sep 20

PMID 39304580

Authors

Susan Creary

Melissa G Chung

Anthony D Villella

Warren D Lo

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Sickle cell anemia (SCA) is an autosomal recessive inherited hemoglobinopathy that results in a high risk of stroke. SCA primarily affects an underserved minority population of children who are frequently not receiving effective, multi-disciplinary, preventative care. This article reviews primary and secondary stroke prevention and treatment for children with SCA for the general adult and pediatric neurologist, who may play an important role in providing critical neurologic evaluation and care to these children.

Recent Findings: Primary stroke prevention is efficacious at reducing ischemic stroke risk, but it is not consistently implemented into clinical practice in the United States, resulting in these children remaining at high risk. Acute symptomatic stroke management requires neurology involvement and emergent transfusion to limit ischemia. Furthermore, while chronic transfusion therapy is a proven secondary preventative modality for those with prior symptomatic or silent cerebral infarcts, it carries significant burden. Newer therapies (e.g., stem cell therapies and voxelotor) deserve further study as they may hold promise in reducing stroke risk and treatment burden. Effective primary and secondary stroke prevention and treatment remain a challenge. Informing and engaging neurology providers to recognize and provide critical neurologic evaluation and treatment has potential to close care gaps.

References

Carpenter J, Nickel R, Webb J, Khademian Z, Speller-Brown B, Majumdar S . Low Rates of Cerebral Infarction after Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease at High Risk for Stroke. Transplant Cell Ther. 2021; 27(12):1018.e1-1018.e9. DOI: 10.1016/j.jtct.2021.08.026. View

Fullerton H, Wu Y, Zhao S, Johnston S . Risk of stroke in children: ethnic and gender disparities. Neurology. 2003; 61(2):189-94. DOI: 10.1212/01.wnl.0000078894.79866.95. View

DeBaun M, Derdeyn C, McKinstry 3rd R . Etiology of strokes in children with sickle cell anemia. Ment Retard Dev Disabil Res Rev. 2006; 12(3):192-9. DOI: 10.1002/mrdd.20118. View

Frangoul H, Altshuler D, Cappellini M, Chen Y, Domm J, Eustace B . CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med. 2020; 384(3):252-260. DOI: 10.1056/NEJMoa2031054. View

Gaston M, Verter J, Woods G, Pegelow C, Kelleher J, Presbury G . Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986; 314(25):1593-9. DOI: 10.1056/NEJM198606193142501. View

Amlie-Lefond C, Flanagan J, Kanter J, Dobyns W . The Genetic Landscape of Cerebral Steno-Occlusive Arteriopathy and Stroke in Sickle Cell Anemia. J Stroke Cerebrovasc Dis. 2018; 27(11):2897-2904. DOI: 10.1016/j.jstrokecerebrovasdis.2018.06.004. View

DeBaun M, Gordon M, McKinstry R, Noetzel M, White D, Sarnaik S . Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014; 371(8):699-710. PMC: 4195437. DOI: 10.1056/NEJMoa1401731. View

Rallo M, Akel O, Kalakoti P, Sun H . Characteristics and outcomes of stroke hospitalizations in patients with sickle cell disease and moyamoya syndrome. J Stroke Cerebrovasc Dis. 2022; 31(10):106705. DOI: 10.1016/j.jstrokecerebrovasdis.2022.106705. View

Hulbert M, McKinstry R, Lacey J, Moran C, Panepinto J, Thompson A . Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2010; 117(3):772-9. PMC: 3035071. DOI: 10.1182/blood-2010-01-261123. View

10.

Ware R, Davis B, Schultz W, Brown R, Aygun B, Sarnaik S . Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2015; 387(10019):661-670. PMC: 5724392. DOI: 10.1016/S0140-6736(15)01041-7. View

11.

Aumann M, Richerson W, Song A, Davis L, Pruthi S, Davis S . Cerebral hemodynamic changes after haploidentical hematopoietic stem cell transplant in adults with sickle cell disease. Blood Adv. 2023; 8(3):608-619. PMC: 10838697. DOI: 10.1182/bloodadvances.2023010717. View

12.

Prussien K, Compas B, Siciliano R, Ciriegio A, Lee C, Kassim A . Cerebral Hemodynamics and Executive Function in Sickle Cell Anemia. Stroke. 2021; 52(5):1830-1834. PMC: 8483619. DOI: 10.1161/STROKEAHA.120.032741. View

13.

Kassim A, Pruthi S, Day M, Rodeghier M, Gindville M, Brodsky M . Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia. Blood. 2016; 127(16):2038-40. DOI: 10.1182/blood-2016-01-694562. View

14.

Ferriero D, Fullerton H, Bernard T, Billinghurst L, Daniels S, DeBaun M . Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2019; 50(3):e51-e96. DOI: 10.1161/STR.0000000000000183. View

15.

Newman S, McMahon J, Boulter J, Malcolm J, Revuelta Barbero J, Chern J . Revascularization Is Associated With a Reduced Stroke Risk in Patients With Sickle Cell-Associated Moyamoya Syndrome. Neurosurgery. 2022; 90(4):441-446. DOI: 10.1227/NEU.0000000000001847. View

16.

Griessenauer C, Lebensburger J, Chua M, Fisher 3rd W, Hilliard L, Bemrich-Stolz C . Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr. 2015; 16(1):64-73. DOI: 10.3171/2014.12.PEDS14522. View

17.

Kelleher S, Kirkham F, Hood A . Executive Function and Processing Speed in Children Living with Sickle Cell Anemia. Children (Basel). 2023; 10(10). PMC: 10605810. DOI: 10.3390/children10101585. View

18.

Kato G, Piel F, Reid C, Gaston M, Ohene-Frempong K, Krishnamurti L . Sickle cell disease. Nat Rev Dis Primers. 2018; 4:18010. DOI: 10.1038/nrdp.2018.10. View

19.

Bhattacharya P, Sarmah D, Dave K, Goswami A, Watanabe M, Wang X . Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries. J Neurol Sci. 2021; 427:117510. DOI: 10.1016/j.jns.2021.117510. View

20.

Stollon N, Paine C, Lucas M, Brumley L, Poole E, Peyton T . Transitioning Adolescents and Young Adults With Sickle Cell Disease From Pediatric to Adult Health Care: Provider Perspectives. J Pediatr Hematol Oncol. 2015; 37(8):577-83. PMC: 4806545. DOI: 10.1097/MPH.0000000000000427. View